Free Trial
NYSE:ADCT

ADC Therapeutics Q2 2025 Earnings Report

ADC Therapeutics logo
$3.30 +0.15 (+4.60%)
Closing price 03:59 PM Eastern
Extended Trading
$3.24 -0.05 (-1.67%)
As of 05:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ADC Therapeutics EPS Results

Actual EPS
N/A
Consensus EPS
-$0.36
Beat/Miss
N/A
One Year Ago EPS
N/A

ADC Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$17.82 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

ADC Therapeutics Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Tuesday, August 5, 2025
Conference Call Time
8:30AM ET

Conference Call Resources

ADC Therapeutics Earnings Headlines

ADCT - ADC Therapeutics SA Financials - Morningstar
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
- Related Stocks: NYSE:ADCT,
See More ADC Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ADC Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ADC Therapeutics and other key companies, straight to your email.

About ADC Therapeutics

ADC Therapeutics (NYSE:ADCT) is a clinical-stage biopharmaceutical company focused on the development and commercialization of antibody-drug conjugates (ADCs) to treat hematological malignancies and solid tumors. Utilizing its proprietary pyrrolobenzodiazepine (PBD) cytotoxin platform, the company designs targeted therapies that deliver powerful anti-cancer agents directly to tumor cells while minimizing systemic exposure. ADC Therapeutics oversees all stages of drug development from discovery and preclinical evaluation through clinical trials and regulatory approval.

The company’s lead product, loncastuximab tesirine (marketed as Zynlonta), received regulatory approval for the treatment of relapsed or refractory large B-cell lymphoma. Beyond this first-in-class ADC, ADC Therapeutics has multiple additional candidates in its pipeline, including camidanlumab tesirine for Hodgkin lymphoma and several earlier-stage programs targeting solid tumors and other blood cancers. The organization collaborates with academic institutions and industry partners to explore combination therapies, expand indications, and enhance the therapeutic potential of its ADC platform.

Founded in 2011 as a spin-out of the UK-based ADC specialist Spirogen, ADC Therapeutics is headquartered in Lausanne, Switzerland, with a major research and development hub in Princeton, New Jersey. The company completed its initial public offering on the New York Stock Exchange in 2018 under the ticker ADCT. Led by an experienced management team with deep expertise in oncology drug development and commercialization, ADC Therapeutics continues to execute its strategic vision of bringing targeted, high-potency cancer therapies to patients worldwide.

View ADC Therapeutics Profile

More Earnings Resources from MarketBeat